Methods and compositions for modulating regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor
CA 2434671 A1 · Owner: Metz, Christine · Inventors: Bucala, Richard; Abe, Riichiro; Metz, Christine
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Regulation of expression of CTL activity by macrophage migration inhibitory factor (MIF) is disclosed. In a mouse model using the EL4 tumor cultured , splenocytes from tumor-primed mice secrete high levels of MIF following antigen stimulation in vitro. Parallel splenocytes treated with neutralizing anti-MIF mAb showed a significant increase in CTL response against tumor cells compared to control mAb-treated cultures with elevated expression of IFN , .gamma.. Histology of tumors from anti-MIF treated animals showed increases in infiltration of both CD4+ and CD8+ T cells as well as apoptotic tumor cells, consistent with observed augmentation of CTL activity in vivo by anti-MIF which was …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 14, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 14, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 14, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.